BioVersys to Report Its Full Year 2025 Financial Results, Provide a Business Update and Host a Conference Call
BASEL, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria, announced today the reporting of its Full Year 2025 financial results, along with a business update and the hosting of an investor, analyst and media conference call.
The company will publish its Full Year 2025 financial results on March 18, 2026. On the reporting date, BioVersys will issue a press release at 7:00 AM CET / 2:00 AM ET.
Following the release, BioVersys will host a conference call and webcast on March 18, 2026 at 2:00 PM CET / 9:00 AM ET where management will review the financial result
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.